港股異動 | 亞盛醫藥-B(6855.HK)一度漲近9% 2020年共獲得9項FDA孤兒藥認證
格隆匯1月11日丨亞盛醫藥-B(6855.HK)午後快速拉漲,一度升至近9%,現報39.4港元,暫成交5252萬港元,總市值89億港元。日前亞盛醫藥-B又獲一項美國FDA孤兒藥認證,於2020年共有4個在研新藥獲得共9項FDA孤兒藥認證,創中國生物醫藥企業之最。獲得FDA孤兒藥認定等資格認定也被視為重要的全球化創新實力指標之一。另外,在2020年12月25日,上交所和深交所同時發佈《港股通股票名單調整公吿》,亞盛醫藥等6支B類醫藥股被納入港股通名單。業內人士指出,在被納入港股通標的後,B類醫藥股中有望出現持續上漲。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.